Initial public offering of Biovitrum (SE) — SEK 770 million
Carnegie acted as global co-ordinator and sole book-runner in the initial public offering of Biovitrum on the O-list of the Stockholm Stock Exchange. The base share offer was more than 10 times subscribed, and a total of 7,700,000 shares were sold in the offering, including the over-allotment option. The price, determined by a book-building process, was set at SEK 100 per share. Biovitrum is one of Europe’s leading biopharma companies with a broad spectrum of activities, from drug discovery, pre-clinical and clinical development to production and marketing and sales.